Shire Selects Model N Government Pricing and FSS Compliance Solutions to Help Reduce Regulatory Risk

Redwood Shores, CA (PRWEB) January 14, 2008 -- Model N, Inc. (http://www.modeln.com), a leader in Revenue Management solutions (http://www.modeln.com/lifeScience/solutions), today announced that Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, has selected Model N's Government Pricing and FSS Compliance applications to improve its regulatory compliance processes.

With global headquarters in Basingstoke, UK, and North American headquarters in Philadelphia, Pennsylvania, Shire focuses on treatments for attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal and renal diseases. In response to the Deficit Reduction Act of 2005 (DRA) and other complex drug pricing regulations, the company aims to build a world-class compliance infrastructure to reduce regulatory exposure. Shire looked at several competitive products, including a legacy vendor's Government Pricing application, but opted for Model N's offerings due to their superior functionality and integrated architecture.

With Model N Government Pricing (http://www.modeln.com/lifeScience/solutions/pharmaceuticalSuite/governmentPricing.html), Shire is acquiring a powerful solution that ensures transparency and auditability across its government pricing operations. Complementing Government Pricing, Model N FSS Compliance will provide Shire with end-to-end support for Federal Supply Schedule reporting requirements by allowing the company to monitor and disclose all pricing information and avoid violations. Both solutions are components of the best-of-breed Model N Revenue Management Suite, which aligns disparate pricing, contract management, settlements, and regulatory compliance processes on a common platform. The suite has become the preferred solution for financial and sales executives seeking to eliminate revenue leakage and reduce regulatory risk.

"With implementation of the DRA final rule well underway, pharmaceutical leaders such as Shire are faced with the unprecedented challenges of managing accelerating competition and maintaining regulatory compliance," said Sujay Jadhav, Vice President and General Manager of Model N Life Sciences. "After careful consideration of competitive offerings, we appreciate that Shire has placed its trust in Model N to deliver the business processes, policy structures, and robust technology framework needed to comply with the rigid requirements of commercial and government contracting."

About Model N

Model N is the leader in Revenue Management solutions, offering an integrated suite of applications for pricing, contracts, compliance, rebates, fees, and chargebacks optimized for the industry practices of life sciences companies, with the only integrated government pricing and Medicaid claims processing capabilities in the industry. Enabling the creation of a seamless, end-to-end process from pricing through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government pricing and Sarbanes-Oxley regulations. Customers include Astellas Pharma US, Inc.; Axcan Pharma; Boston Scientific; Bristol-Myers Squibb; Gilead Sciences; MedImmune, Inc.; Medtronic, Inc.; Novo Nordisk, Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; and Pfizer, Inc. Model N is located in Redwood Shores, California. For additional information, visit www.modeln.com.

About Shire

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit www.shire.com.

###